Cargando…
Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations
BACKGROUND: Personalized medicine requires accurate molecular profiling for targeted therapy decisions. Insufficient tissue yield or tumor heterogeneity frequently limits the correct tissue biomarker determination. As a noninvasive complement to traditional tissue biopsies, liquid biopsies detect an...
Autores principales: | Poole, Jason C., Wu, Shan-Fu, Lu, Timothy T., Vibat, Cecile Rose T., Pham, Anh, Samuelsz, Errin, Patel, Manisha, Chen, Jeffrey, Daher, Tony, Singh, Veena M., Arnold, Lyle J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776432/ https://www.ncbi.nlm.nih.gov/pubmed/31581267 http://dx.doi.org/10.1371/journal.pone.0223112 |
Ejemplares similares
-
Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021) -
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014) -
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014) -
EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013) -
Selectors
por: Jayne, John E, et al.
Publicado: (2001)